keyword
MENU ▼
Read by QxMD icon Read
search

Radiation Pneumonitis

keyword
https://www.readbyqxmd.com/read/28211612/genetic-variants-in-the-plasminogen-activator-inhibitor-1-gene-are-associated-with-an-increased-risk-of-radiation-pneumonitis-in-lung-cancer-patients
#1
Bo Liu, Yang Tang, Minxiao Yi, Qingxu Liu, Huihua Xiong, Guangyuan Hu, Xianglin Yuan
Plasminogen activator inhibitor-1 (PAI-1) plays a crucial role in the process of lung injury, although its association with radiation pneumonitis (RP) is unclear. We hypothesized that genetic variants in PAI-1 may influence the risk of RP. In this study, 169 lung cancer patients were genotyped for six single-nucleotide polymorphisms in PAI-1 using the Sequenom MassARRAY system. The risk of RP was evaluated by Cox proportional hazards analyses. The cumulative RP probabilities by genotype were assessed using Kaplan-Meier analyses...
February 17, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28208025/aeol-10150-mitigates-radiation-induced-lung-injury-in-the-nonhuman-primate-morbidity-and-mortality-are-administration-schedule-dependent
#2
Thomas J MacVittie, Allison Gibbs, Ann M Farese, Kory Barrow, Alexander Bennett, Cheryl Taylor-Howell, Abdul Kazi, Karl Prado, George Parker, William Jackson Iii
Pneumonitis and fibrosis are potentially lethal, delayed effects of acute radiation exposure. In this study, male rhesus macaques received whole-thorax lung irradiation (WTLI) with a target dose of 10.74 Gy prescribed to midplane at a dose rate of 0.80 ± 0.05 Gy/min using 6 MV linear accelerator-derived photons. The study design was comprised of four animal cohorts: one control and three treated with AEOL 10150 (n = 20 animals per cohort). AEOL 10150, a metalloporphyrin antioxidant, superoxide dismutase mimetic was administered by daily subcutaneous injection at 5 mg/kg in each of three schedules, beginning 24 ± 2 h postirradiation: from day 1 to day 28, day 1 to day 60 or a divided regimen from day 1 to day 28 plus day 60 to day 88...
February 16, 2017: Radiation Research
https://www.readbyqxmd.com/read/28195507/predicting-risk-factors-for-radiation-pneumonitis-after-stereotactic-body-radiation-therapy-for-primary-or-metastatic-lung-tumors
#3
Mitsuru Okubo, Tomohiro Itonaga, Tatsuhiko Saito, Sachika Shiraishi, Ryuji Mikami, Hidetugu Nakayama, Akira Sakurada, Shinji Sugahara, Kiyoshi Koizumi, Koichi Tokuuye
OBJECTIVES: To investigate risk factors for radiation-induced pneumonitis (RP) after hypofractionated stereotactic body radiotherapy (SBRT) in patients with lung tumors. METHODS: From May 2004 to January 2016, 66 patients with 71 primary or metastatic lung tumors were treated with SBRT; these 71 cases were retrospectively analyzed for RP. To explore the risk factors for RP, the following factors were investigated: age, sex, performance status, operability, number of treatments, respiratory gating, pulmonary emphysema, tumor location, and subclinical interstitial lung disease (ILD)...
February 14, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28189065/the-pulmonary-fibrosis-associated-muc5b-promoter-polymorphism-is-prognostic-of-the-overall-survival-in-patients-with-non-small-cell-lung-cancer-nsclc-receiving-definitive-radiotherapy
#4
Ju Yang, Ting Xu, Daniel R Gomez, Melenda Jeter, Lawrence B Levy, Yipeng Song, Stephen Hahn, Zhongxing Liao, Xianglin Yuan
BACKGROUND: MUC5B is glycoprotein secreted by bronchial glands. A promoter variant in MUC5B, rs35705950, was previously found to be strongly associated with the incidence of idiopathic pulmonary fibrosis (IPF) and also the overall survival (OS) of such patients. Patients with IPF and patients with radiation pneumonitis (RP) have the similar pathologic process and clinical symptoms. However, the role of rs35705950 in patients receiving thoracic radiotherapy remains unclear. PATIENTS AND METHODS: In total, 664 patients with NSCLC receiving definitive radiotherapy (total dose ≥60 Gy) were included in our study...
February 8, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28183160/long-term-outcomes-after-salvage-radiotherapy-for-postoperative-locoregionally-recurrent-non-small-cell-lung-cancer
#5
Eunji Kim, Changhoon Song, Mi Young Kim, Jae-Sung Kim
Purpose: The outcomes and toxicities of locoregionally recurrent non-small-cell lung cancer (NSCLC) patients treated with curative radiotherapy were evaluated in the modern era. Materials and Methods: Fifty-seven patients receiving radical radiotherapy for locoregionally recurrent NSCLC without distant metastasis after surgery from 2004 to 2014 were reviewed. Forty-two patients were treated with concurrent chemoradiotherapy (CCRT), and 15 patients with radiotherapy alone...
February 13, 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/28168165/innate-immune-pathways-associated-with-lung-radioprotection-by-soy-isoflavones
#6
Lisa M Abernathy, Matthew D Fountain, Michael C Joiner, Gilda G Hillman
INTRODUCTION: Radiation therapy for lung cancer causes pneumonitis and fibrosis. Soy isoflavones protect against radiation-induced lung injury, but the mediators of radioprotection remain unclear. We investigated the effect of radiation on myeloid-derived suppressor cells (MDSCs) in the lung and their modulation by soy isoflavones for a potential role in protection from radiation-induced lung injury. METHODS: BALB/c mice (5-6 weeks old) received a single 10 Gy dose of thoracic irradiation and soy isoflavones were orally administrated daily before and after radiation at 1 mg/day...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28164664/serum-amyloid-p-component-level-may-be-a-biomarker-for-lung-toxicities-and-overall-survival-after-thoracic-radiotherapy-for-non-small-cell-lung-cancer
#7
Jing Zhao, Alexander Chi, Rui Mao, Guangyuan Hu, Minghua Ji
BACKGROUND: Serum amyloid P-component (SAP) contributes to the clearance of apoptotic cells. As one of the main acute-phase reactants, SAP regulates key aspects of inflammation and sets a threshold for immune cell activation. This study aimed to investigate the association of SAP levels with symptomatic lung toxicities after thoracic radiotherapy (TRT) and overall survival (OS) in non-small lung cancer (NSCLC) patients. METHODS: The SAP level at diagnosis and during TRT was evaluated by ELISA in 113 clinically inoperable NSCLC patients...
November 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28162946/first-clinical-report-of-proton-beam-therapy-for-postoperative-radiotherapy-for-non-small-cell-lung-cancer
#8
Jill S Remick, Caitlin Schonewolf, Peter Gabriel, Abigail Doucette, William P Levin, John C Kucharczuk, Sunil Singhal, Taine T V Pechet, Ramesh Rengan, Charles B Simone, Abigail T Berman
BACKGROUND AND PURPOSE: The characteristic Bragg peak of proton beam therapy (PBT) allows for sparing normal tissues beyond the tumor volume that may allow for decreased toxicities associated with postoperative radiation therapy (PORT). Here we report the first institutional experience with proton therapy for PORT in patients with non-small-cell lung cancer (NSCLC) and assess early toxicities and outcomes. MATERIALS AND METHODS: We identified 61 consecutive patients treated from 2011 to 2014 who underwent PORT for locally advanced NSCLC for positive microscopic margins and/or positive N2 lymph nodes (stage III), with 27 patients receiving PBT and 34 receiving intensity-modulated radiation therapy (IMRT)...
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28161553/lower-incidence-of-esophagitis-in-the-elderly-undergoing-definitive-radiation-therapy-for-lung-cancer
#9
Payal D Soni, Philip S Boonstra, Matthew J Schipper, Latifa Bazzi, Robert T Dess, Martha M Matuszak, Feng-Ming Kong, James A Hayman, Randall K Ten Haken, Theodore S Lawrence, Gregory P Kalemkerian, Shruti Jolly
INTRODUCTION: Most patients with lung cancer are elderly and poorly represented in randomized clinical trials. They are often undertreated because of concerns about their ability to tolerate aggressive treatment. We tested the hypothesis that elderly patients undergoing definitive lung radiation might tolerate treatment differently than younger patients. METHODS: A total of 125 patients who underwent definitive lung radiotherapy were identified from a prospective institutional database (University of Michigan cohort)...
March 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28149588/pemetrexed-induced-radiation-recall-dermatitis-in-a-patient-with-lung-adenocarcinoma-case-report-and-literature-review
#10
Jin Ge, Vivek Verma, Andrew Hollander, Corey Langer, Charles B Simone
Radiation recall dermatitis (RRD) is an inflammatory reaction in a previously irradiated field subsequent to the administration of pharmacologic or promoting agents. Herein, we describe a 47-year-old man with NSCLC who was treated with radiotherapy and pemetrexed-based chemotherapy three years prior to developing RRD upon resumption of pemetrexed-based chemotherapy. RRD with pemetrexed is rare and consists of five cases reported thus far. Although RRD is a rare phenomenon, it should be considered in any patient with dermatologic reactions that occur at the site of previous exposure to radiation therapy...
December 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28139305/long-term-outcome-of-phase-i-ii-prospective-study-of-dose-escalated-proton-therapy-for-early-stage-non-small-cell-lung-cancer
#11
Joe Y Chang, Wencheng Zhang, Ritsuko Komaki, Noah C Choi, Shen Chan, Daniel Gomez, Michael O'Reilly, Melenda Jeter, Michael Gillin, Xiaorong Zhu, Xiaodong Zhang, Radhe Mohan, Stephen Swisher, Stephen Hahn, James D Cox
PURPOSE: The aim of this phase I/II study was to assess the long-term clinical benefits and toxicities of proton beam therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: From June 2006 to September 2011, 35 patients with medically inoperable T1N0M0 (central or superior location, 12 patients) or T2-3N0M0 (any location, 23 patients) NSCLC were treated with 87.5Gy at 2.5Gy/fraction of proton therapy. Toxicities were scored according to the Common Terminology Criteria for Adverse Events, version 4...
January 27, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28137739/etoposide-and-cisplatin-vs-paclitaxel-and-carboplatin-with-concurrent-thoracic-radiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-a-multicenter-randomized-phase-iii-trial
#12
J Liang, N Bi, S Wu, M Chen, C Lv, L Zhao, A Shi, W Jiang, Y Xu, Z Zhou, W Wang, D Chen, Z Hui, J Lv, H Zhang, Q Feng, Z Xiao, X Wang, L Liu, T Zhang, L Du, W Chen, Y Shyr, W Yin, J Li, J He, L Wang
BACKGROUND: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multi-center phase III trial was conducted to compare the efficacy of concurrent thoracic radiation therapy (TRT) with either etoposide/cisplatin (EP) or carboplatin/paclitaxel (PC) in patients with stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were randomly received 60 to 66 Gy of TRT concurrent with either etoposide 50 mg/m(2) on days 1 to 5 and cisplatin 50 mg/m(2) on days 1 and 8 every 4 weeks for two cycles (EP arm), or paclitaxel 45 mg/m(2) and carboplatin (AUC 2) on day 1 weekly (PC arm)...
January 30, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28133305/-a-case-of-rectal-cancer-successfully-treated-with-surgery-and-stereotactic-radiotherapy-for-metachronous-lung-metastases
#13
Yu Oshima, Yohei Hosoda, Hidekazu Tachi, Takashi Sugimoto, Asami Okabe, Kazuhiro Nishiyama, Nobuko Ogura, Izumi Komoto, Hidenori Kiyochi, Shoji Tsunekawa, Toru Tanaka, Yoshiro Taki, Masayuki Imamura
A 64-year-old woman underwent polypectomy for a rectal polyp(Isp). Pathological findings were invasion of the submucosa( 3,500 mm diameter), and she underwent anterior resection for rectal cancer(RS, pT1b, pN0, cM0, Stage I )without adjuvant chemotherapy. Lung masses were found in her right(8mm)and left lung(7mm). The tumors enlarged during the 4 month follow-up period. We decided to perform left partial pneumonectomy. The tumor was diagnosed as a lung metastasis from colon cancer by pathology. Because the right tumor was located towards the center, performing right pneumonectomy would have been quite invasive and we feared occult metastases...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28130353/gene-expression-profiles-among-murine-strains-segregate-with-distinct-differences-in-the-progression-of-radiation-induced-lung-disease
#14
Isabel L Jackson, Fitsum Baye, Chirayu P Goswami, Barry P Katz, Andrew Zodda, Radmila Pavlovic, Ganga Gurung, Don Winans, Zeljko Vujaskovic
Molecular mechanisms underlying development of acute pneumonitis and/or late fibrosis following thoracic irradiation remain poorly understood. Here we hypothesize that heterogeneity in disease progression and phenotypic expression of radiation-induced lung disease (RILD) across murine strains presents an opportunity to better elucidate mechanisms driving tissue response toward pneumonitis and/or fibrosis. In this study distinct differences in disease progression were observed in age- and sex-matched CBA/J, C57L/J, and C57BL/6J mice over 1 y after graded doses of whole-thorax lung irradiation (WTLI)...
January 26, 2017: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/28126305/hypofractionated-regional-nodal-irradiation-for-women-with-node-positive-breast-cancer
#15
Sara Bellefqih, Sanaa Elmajjaoui, Jihan Aarab, Jihane Khalil, Mohamed Afif, Amine Lachgar, Hanan El Kacemi, Tayeb Kebdani, Noureddine Benjaafar
PURPOSE: To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement. METHODS AND MATERIALS: Two hundred fifty-seven patients treated between October 2009 and June 2011 with hypofractionated locoregional radiation therapy (42 Gy in 15 fractions) were retrospectively reviewed, 51 (19...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28123916/stereotactic-body-radiotherapy-for-inoperable-liver-tumors-results-of-a-single-institutional-experience
#16
Hussam Hijazi, Marie-Pierre Campeau, David Roberge, David Donath, Real Lapointe, Franck Vandenbroucke-Menu, Daniel Taussky, Karim Boudam, Gabriel Chan, Alexis Bujold, Guila Delouya
OBJECTIVES: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for liver tumors unsuitable for ablation or surgery. We report our experience with SBRT in the treatment of liver tumors. MATERIALS AND METHODS: Patients with primary or secondary liver cancer were identified in our local SBRT database. Patients were included irrespective of prior liver-directed therapies. The primary endpoint of our review was in-field local control (LC). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity...
December 20, 2016: Curēus
https://www.readbyqxmd.com/read/28122893/clinical-outcomes-of-stereotactic-ablative-radiotherapy-in-patients-with-pulmonary-metastasis
#17
Bum-Sup Jang, Hak Jae Kim, Byoung Hyuck Kim, Dong-Wan Kim, Young Tae Kim, Young Whan Kim, Myoung-Jin Jang, Hong-Gyun Wu
BACKGROUNDS: In addition to its curative use for early stage lung cancer, stereotactic ablative radiotherapy is also indicated for pulmonary metastatic disease. Aims of this study were to retrospectively analyze treatment outcomes and to find prognostic factors for survivals. METHODS: Treatment outcomes and toxicities of 85 cases of SABR in 72 patients were retrospectively reviewed from September 2012 to April 2015. Prognostic factors were analyzed using Cox proportional hazards regression...
January 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28122566/intentional-avoidance-of-the-esophagus-using-intensity-modulated-radiation-therapy-to-reduce-dysphagia-after-palliative-thoracic-radiation
#18
Patrick V Granton, David A Palma, Alexander V Louie
BACKGROUND: Palliative thoracic radiotherapy is an effective technique to alleviate symptoms of disease burden in advanced-stage lung cancer patients. Previous randomized controlled studies demonstrated a survival benefit in patients with good performance status at radiation doses of 35Gy10 or greater but with an increased incidence of esophagitis. The objective of this planning study was to assess the potential impact of esophageal-sparing IMRT (ES-IMRT) compared to the current standard of care using parallel-opposed pair beams (POP)...
January 26, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28117611/long-term-outcomes-of-intensity-modulated-radiotherapy-following-extra-pleural-pneumonectomy-for-malignant-pleural-mesothelioma
#19
Yukinori Matsuo, Keiko Shibuya, Kenichi Okubo, Nami Ueki, Akihiro Aoyama, Makoto Sonobe, Mitsuhiro Nakamura, Takashi Mizowaki, Hiroshi Date, Masahiro Hiraoka
BACKGROUND: The purpose was to evaluate safety and efficacy of intensity-modulated radiotherapy (IMRT) following extra-pleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). MATERIAL AND METHODS: Patients with MPM of clinical stage I-III, which were macroscopic completely resected with EPP were eligible for this prospective study. The ipsilateral hemithorax was irradiated with a prescribed dose of 50.4 Gy. When the high-risk surgical margins or FDG-avid regions were identified, simultaneous integrated boost (SIB) with 56...
January 24, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28103970/-a-phase-i-ii-study-of-chemotherapy-concurrent-with-twice-daily-radiotherapy-%C3%A2-schedules-by-intensity-modulated-radiation-therapy-using-simultaneous-integrated-boost-for-limited-stage-small-cell-lung-cancer
#20
Jing You, Huiming Yu, Maxiaowei Song, Chen Shi, Xiaohang Wang, Ye Zheng, Rong Yu, Anhui Shi, Guangying Zhu
BACKGROUND: Twice-daily radiation concurrent with chemotherapy is one of the standard methods for limited-stage small cell lung cancer. The study was to evaluate the feasibility of chemotherapy concurrent with dose-escalating twice-daily radiotherapy by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) approach in patients with limited-stage small cell lung cancer. METHODS: Patients with limited-stage small cell lung cancer were included, treated with twice-daily radiotherapy by SIB-IMRT concurrent with chemotherapy of etoposide plus cisplatin...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
keyword
keyword
11286
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"